Guoke Hengtai: Special report on the storage, management and use of raised funds in the first half of 2026
Securities code: 301370 Securities abbreviation: Guoke Hengtai Announcement number: 2026-048
Guoke Hengtai (Beijing) Medical Technology Co., Ltd.
Special report on the storage, management and use of raised funds in the first half of 2026
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
In accordance with relevant regulations such as the "Supervision Rules for Funds Raised by Listed Companies" and "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operations of GEM Listed Companies", the storage, management and use of funds raised by Guoke Hengtai (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as the "Company") for the first half of 2026 is hereby explained as follows:
1. Basic situation of raised funds
(1) Amount of funds raised and time to receive them
According to the China Securities Regulatory Commission's "Reply on Approving the Registration of the Initial Public Offering of Guoke Hengtai (Beijing) Medical Technology Co., Ltd." (CSRC License [2023] No. 997), the company was approved to publicly issue 70.60 million RMB ordinary shares (A shares) to the public, with a face value of RMB 1.00 per share, an issue price of RMB 13.39 per share, and a total amount of raised funds of RMB 94,533.40. Ten thousand yuan, after deducting the issuance fee of RMB 102.1249 million (excluding value-added tax), the actual net raised funds totaled RMB 843.2091 million.
The aforementioned raised funds have been raised by the sponsor (lead underwriter) Great Wall Securities Co., Ltd. on July 5, 2023. On the same day, they were remitted to the company's special account for raised funds opened at the Beijing Pilot Free Trade Zone Branch of Bank of Communications Co., Ltd. (account number is 110060777013005220588), the special account for raised funds opened at Beijing Chang'an Branch of Hua Xia Bank Co., Ltd. (account number is 10253000001112793), and the raised funds opened at Fuyu Branch of Bank of Beijing Co., Ltd. The special account for raising funds (account number is 20000024371300120182624) and the special account for raising funds opened by Beijing Xidan Branch of Industrial Bank Co., Ltd. (account number is 321060100100335445). The above-mentioned receipt of raised funds has been verified by Grant Thornton Accounting Firm (Special General Partnership) issuing the Capital Verification Report No. 110C000322 (2023).
(2) Use of funds raised by the company as of June 30, 2026
Unit: 10,000 yuan
Project Amount Net raised funds 84,320.91 Less: Cumulative amount invested in raised investment projects 52,502.66 Including: Cumulative amount invested in projects at the beginning of the period 50,814.46 Amount invested in projects during the reporting period 1,688.20 Permanent replenishment of working capital with excess raised funds 20,475.00 Permanent replenishment of working capital with surplus raised funds (including interest income) from raised investment projects
1,777.84 conditions
Use of idle raised funds to temporarily replenish working capital -
Financial expenses - bank fees 0.30 plus: Financial expenses - deposit interest income 27.41 Closing balance of raised funds account as of June 30, 2026 9,592.53 Balance of net raised funds as of June 30, 2026 9,592.53 Difference between the closing balance of raised funds account and net raised funds -
Note: There are differences in the mantissa between the total in the above table and the sum of each sub-item, which are all due to rounding.
2. Storage and management of raised funds
(1) Management of raised funds
In order to standardize the management and use of raised funds and protect the rights and interests of investors, the company has formulated the "Measures for the Management of Raised Funds of Guoke Hengtai (Beijing) Medical Technology Co., Ltd." (hereinafter referred to as the "Management Measures") in accordance with the "Regulatory Guidelines for Listed Companies No. 2 - Supervisory Requirements for the Management and Use of Funds Raised by Listed Companies (Revised in 2022)" and "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operations of GEM Listed Companies" and based on the actual situation of the company. On November 27, 2025, and December 16, 2025, the company held the 46th meeting of the third board of directors and the fifth extraordinary general meeting of shareholders in 2025 respectively, and reviewed and approved the "Proposal on Amending the Measures for the Management of Raised Funds".
The company on May 31, 2023 The 11th meeting of the third session of the Board of Directors was held on the same day, and the "Proposal on the Company's Opening of a Raised Funds Account" and the "Proposal on Signing a Supervision Agreement for the Storage of Raised Funds in Special Accounts" were reviewed and approved, and the company was approved to open special accounts for raised funds at Bank of Communications Co., Ltd. Beijing Pilot Free Trade Zone Branch, Hua Xia Bank Co., Ltd. Beijing Chang'an Branch, Bank of Beijing Co., Ltd. Fuyu Branch and Industrial Bank Co., Ltd. Beijing Xidan Branch for the storage, management and use of funds raised by this initial public offering. In June 2023, the company signed a "Tripartite Supervision Agreement on Raised Funds" with Bank of Communications Co., Ltd. Beijing Free Trade Zone Branch, Huaxia Bank Co., Ltd. Beijing Chang'an Branch, Bank of Beijing Co., Ltd. Fuyu Branch, Industrial Bank Co., Ltd. Beijing Xidan Branch and Great Wall Securities Co., Ltd. In November 2023, the company and its wholly-owned subsidiaries Guangdong Guoke Hengtai Medical Technology Co., Ltd., Chongqing Guoke Ruiyu Medical Technology Co., Ltd., Bank of Communications Co., Ltd. Beijing Free Trade Zone Branch and Great Wall Securities Co., Ltd. signed the "Tripartite Supervision Agreement on Raised Funds".
The company held the 14th meeting of the third board of directors and the fifth meeting of the third board of supervisors on August 28, 2023, and reviewed and approved the "Proposal on Adding Implementing Entities for Investment Projects with Partial Raised Funds and Using Part of the Raised Funds to Provide Borrowings to Wholly-Owned Subsidiaries to Implement Raised Investment Projects." The company's information system upgrade construction project implementation entity was newly added to Guoke Hengxing (Beijing) Medical Technology Co., Ltd. In September 2023, the company and its wholly-owned subsidiary Guoke Hengxing (Beijing) Medical Technology Co., Ltd., Huaxia Bank Co., Ltd. Beijing Changan Branch and Great Wall Securities Co., Ltd. signed the "Tripartite Supervision Agreement on Raised Funds".
Company on December 27, 2023 The 22nd meeting of the third board of directors and the 10th meeting of the third board of supervisors held on the same day reviewed and approved the "Proposal on changing the implementation entity, implementation location and extension of some fundraising projects and using part of the raised funds to provide loans to wholly-owned subsidiaries to implement the fundraising projects". The company's third-party medical device logistics construction project implementation entities were changed from Guangdong Guoke Hengtai Medical Technology Co., Ltd. and Chongqing Guoke Ruiyu Medical Technology Co., Ltd. to Guangdong Guoke Hengtai Medical Technology Co., Ltd. and Guoke Hengxiang (Tianjin) Medical Technology Co., Ltd. In April 2024, Guoke Hengxiang (Tianjin) Medical Technology Co., Ltd., Bank of Communications Co., Ltd. Beijing Free Trade Zone Branch and Great Wall Securities Co., Ltd. signed the "Tripartite Supervision Agreement on Raised Funds"; and canceled the special account for raised funds opened by Chongqing Guoke Ruiyu Medical Technology Co., Ltd. As of December 31, 2024, the company and its wholly-owned subsidiaries Guangdong Guoke Hengtai Medical Technology Co., Ltd. (hereinafter referred to as "Guangdong Guoke"), Guoke Hengxiang (Tianjin) Medical Technology Co., Ltd. (hereinafter referred to as "Tianjin Hengxiang"), Bank of Communications Co., Ltd. Beijing Free Trade Zone Branch and Great Wall Securities Co., Ltd. signed the "Tripartite Supervision Agreement on Raised Funds".
The company held the 41st meeting of the third board of directors and the 23rd meeting of the third board of supervisors on July 3, 2025, and reviewed and approved the "Proposal on Using Part of Idle Raised Funds to Temporarily Supplement Working Capital" and agreed to use idle raised funds (including over-raised funds) not exceeding RMB 92.75 million to temporarily replenish working capital. If a listed company uses idle raised funds to temporarily replenish working capital, it should do so through a special account for raised funds. After deliberation and approval by the company's board of directors, it was agreed that the company would open a special account for raised funds at the Bank of China as an account for temporarily supplementing working capital with idle raised funds (including over-raised funds). In July 2025, the company signed the "Tripartite Supervision Agreement on Raised Funds" with the sponsor Great Wall Securities Co., Ltd. and Bank of China Co., Ltd. Beijing Branch.
As of June 30, 2026, the company has deposited, managed and used the raised funds in strict accordance with the tripartite supervision agreement on such raised funds. There are no major differences between the above-mentioned signed three-party supervision agreement and the Shenzhen Stock Exchange's "Tripartite Supervision Agreement for Raised Funds (Template)", and there are no problems with the performance of the three-party supervision agreement.
(2) Storage status of raised funds in special account
As of June 30, 2026, the specific deposit status of the raised funds is as follows:
Unit: 10,000 yuan
Bank where the account is opened Bank account number Account type Storage balance Industrial Bank Beijing Xidan Branch 321060100100335445 Special account for raised funds 2,283.24 Huaxia Bank Beijing Changan Branch 10253000001112793 Special account for raised funds 5,274.90 Huaxia Bank Beijing Changan Branch 10253000001122916 Special account for raised funds 3.53 Bank of Communications Beijing Pilot Free Trade Zone
110060777013005220588 Special account for raised funds 2,026.96 branch
Bank of Communications Beijing Pilot Free Trade Zone
110060777013006527150 Special account for raised funds 3.82 branch
Bank of China Beijing Branch is open
333776435619 Special account for raising funds 0.08 units
Bank of Communications Beijing Pilot Free Trade Zone
110060777013005971700 Special account for raised funds Closed account branch
Bank of Communications Beijing Pilot Free Trade Zone
110060777013005863638 Special account for raised funds Closed account branch
Bank of Beijing Fuyu Branch 20000024371300120182624 Special account for raised funds has been closed
Total 9,592.53
Note: There are differences in the mantissa between the total in the above table and the sum of each sub-item, which are all due to rounding.
The above deposit balance has been included in the interest income of the special account for raised funds of RMB 274,100 and the handling fee of RMB 3,000.
3. Actual use of funds raised in the first half of 2026
- Usage of funds raised for investment projects
For details on the actual use of funds raised in the first half of 2026, please see the attachment: Comparison table on the use of funds raised in the first half of 2026.
- Changes in implementation locations and implementation methods of investment projects with raised funds
During the reporting period, there were no changes in the implementation location or implementation methods of the investment projects with raised funds.
- Advance investment and replacement of raised funds in investment projects
There were no pre-investments and replacements with self-raised funds during the reporting period.
- Use idle raised funds to temporarily supplement working capital
The company's 41st meeting of the third board of directors and the 23rd meeting of the third board of supervisors held on July 3, 2025 reviewed and approved the "Proposal on Using Part of Idle Raised Funds to Temporarily Supplement Working Capital", agreeing to use idle raised funds (including over-raised funds) not exceeding RMB 92.75 million to temporarily replenish working capital, with a period of use not exceeding 12 years from the date of review and approval by the company's board of directors. Months later, the company will promptly return the raised funds to the special account at any time based on the progress and demand of the investment projects.
On June 11, 2026, the company returned all the above-mentioned raised funds of 92.75 million yuan used to temporarily supplement working capital to the company's raised funds account, and the use period did not exceed 12 months. At the same time, the company has notified the sponsor institution and sponsor representative of the return of the above-mentioned raised funds. For details, please refer to the company’s relevant announcements disclosed on cninfo.com.
The company held the 50th meeting of the third session of the Board of Directors on June 25, 2026, and reviewed and approved the "Proposal on Using Part of Idle Raised Funds to Temporarily Supplement Working Capital" and agreed to use idle raised funds not exceeding RMB 50 million (inclusive) to temporarily replenish working capital. The use period shall not exceed 12 months from the date of review and approval by the company's board of directors. The company will promptly return the raised funds to the special account for raised funds at any time based on the progress and demand of the investment projects.
- Usage of surplus raised funds
Company on November 27, 2025 On the same day, the 46th meeting of the third board of directors and the 26th meeting of the third board of supervisors were held, and the "Proposal on Closing Part of the Investment Project with Raised Funds and Keeping the Surplus Raised Funds in a Special Account for Raised Fund Management" was reviewed and approved. The part of the company's raised investment project "Third Party Medical Device Logistics Construction Project" implemented by Tianjin Hengxiang has reached the intended usable state. The company will close the raised investment project and continue to deposit the remaining raised funds in the special account for raised funds for special account management. The company held the fifth extraordinary shareholders' meeting of 2025 on December 16, 2025 to review and approve this proposal.
The company held the 50th meeting of the third board of directors on June 25, 2026, and reviewed and approved the "Proposal on using part of the surplus raised funds for new projects and using part of the raised funds to provide loans to wholly-owned subsidiaries to implement new projects." It is agreed that the company will use part of the remaining raised funds of the "Third-party Medical Device Logistics Construction Project" from the original raised funds to invest 7.9332 million yuan in the form of a loan to its wholly-owned subsidiary Guoke Zhihe (Tianjin) Medical Technology Co., Ltd. for the construction of the "Medical Device R&D and Production Center Project" (the name of the project will be subject to the final filing with the administrative approval agency). This matter has been reviewed and approved at the 2026 Second Extraordinary Shareholders Meeting held on July 15, 2026.
- Usage of super-raised funds
The actual net amount of funds raised by the company's initial public offering of stocks was RMB 843.2091 million. After deducting the need for investment projects with raised funds, the company's excess raised funds was RMB 227.5041 million.
The company held the 13th meeting of the third board of directors and the fourth meeting of the third board of supervisors on August 2, 2023, and reviewed and approved the "Proposal on Using Part of the Super-raised Funds to Permanently Supplement Working Capital", and agreed that the company would use 68.25 million yuan of super-raised funds to permanently supplement working capital for the company's production and operation activities. The company held the third extraordinary shareholders' meeting of 2023 on August 18, 2023 to review and approve this proposal.
The company held the 28th meeting of the third board of directors and the 14th meeting of the third board of supervisors on July 12, 2024, and reviewed and approved the "Proposal on Using Part of the Super-raised Funds to Permanently Supplement Working Capital", and agreed that the company would use 68.25 million yuan of super-raised funds to permanently supplement working capital for the company's production and operation activities. The company held the second extraordinary shareholders' meeting of 2024 on July 30, 2024 to review and approve this proposal.
The company held the 40th meeting of the third board of directors and the 22nd meeting of the third board of supervisors on June 23, 2025, and reviewed and approved the "Proposal on Using Part of the Super Raised Funds to Permanently Supplement Working Capital" respectively, and agreed that the company would use 68.25 million yuan of super raised funds to permanently supplement working capital for the company's production and operation activities. The company held the second extraordinary shareholders' meeting of 2025 on July 9, 2025 to review and approve this proposal.
The company held the 41st meeting of the third board of directors and the 23rd meeting of the third board of supervisors on July 3, 2025. They reviewed and approved the "Proposal on Using Part of Idle Raised Funds to Temporarily Supplement Working Capital" respectively, and agreed to use idle raised funds (including super-raised funds) of no more than RMB 92.75 million to temporarily replenish working capital. The use period shall not exceed 12 years from the date of review and approval by the company's Board of Directors. Months later, the company will promptly return the raised funds to the special account at any time based on the progress and demand of the investment projects.
The company held the 50th meeting of the third board of directors on June 25, 2026, and reviewed and approved the "Proposal on Using the Remaining Over-raised Funds to Permanently Supplement Working Capital", agreeing that the company will use the remaining over-raised funds of 22.7541 million yuan and all the net interest and fees generated from the over-raised account to permanently replenish working capital. After the remaining over-raised funds are used to permanently replenish working capital this time, and the company's over-raised funds are used up, the company will promptly handle the cancellation procedures for the relevant special account for raised funds in accordance with regulations. The company held the second extraordinary shareholders' meeting of 2026 on July 15, 2026 to review and approve this proposal.
As of June 30, 2026, the company's over-raised funds to temporarily replenish working capital have been returned to the special account for raised funds, and 204.75 million yuan of over-raised funds have been used to permanently replenish working capital.
- The purpose and destination of unused raised funds
As of June 30, 2026, the company's unused raised funds were 95.9253 million yuan (including the net amount of interest income minus bank fees), all of which were deposited in a special account for raised funds.
- Other uses of raised funds
August 28, 2023 On the same day, the company held the 14th meeting of the third board of directors and the fifth meeting of the third board of supervisors, and reviewed and approved the "Proposal on Using Own Funds to Pay Part of the Funds for Raised Investment Projects and Replace them with Raised Funds in Equal Parts". It was agreed that without affecting the normal progress of the investment projects with raised funds, the company and its subsidiaries that implement the investment projects with raised funds plan to use their own funds in advance to pay for the funds required for the raised investment projects during the implementation period of the raised investment projects, based on actual needs and subject to relevant approvals, and then regularly replace them with raised funds in equal amounts.
During the reporting period, except for the situations disclosed above, the company had no other use of raised funds.
4. Change the use of funds raised for investment projects
During the reporting period, the company had no other changes in investment projects with raised funds or changes in the use of raised funds, nor had any previous investment projects with raised funds been transferred or replaced.
5. Problems in the use and disclosure of raised funds
In the first half of 2026, the company disclosed the storage, management and use of raised funds in accordance with relevant regulations such as the "Regulations on the Supervision of Funds Raised by Listed Companies", "Supervisory Guidelines for Listed Companies No. 2 - Supervisory Requirements for the Management and Use of Funds Raised by Listed Companies", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operations of GEM Listed Companies" and other relevant regulations.
Attachment: Comparison table of the use of raised funds in the first half of 2026
Board of Directors of Guoke Hengtai (Beijing) Medical Technology Co., Ltd.
August 28, 2026 Guoke Hengtai (Beijing) Medical Technology Co., Ltd.
Special report on the storage, management and use of raised funds in the first half of 2026
Attachments:
Comparison table on the use of raised funds in the first half of 2026
Unit: Total raised funds in 10,000 yuan 84,320.91 Total raised funds invested from January to June 2026 1,688.20 Total raised funds changed in use during the reporting period -
Cumulative total amount of raised funds that have been changed in use - Cumulative total amount of raised funds that have been invested 72,977.66 Proportion of cumulative total amount of raised funds that have been changed in use -
Is the project feasible?
Adjusted investment as of period end
Commitment to invest in projects Raised funds As of the end of the reporting period
Changes to items in this reporting period: Can the project achieve the scheduled results? Whether the performance is achieved?
Total investment progress
Hechao raised capital investment, committed investment, cumulative investment, achieved results
Project (including parts) Investment amount In-use status date Estimated benefits Significant changes Total Amount (2) Benefits
change) (1) (3)=(2)/(1) commitment investment project
Third-party medical devices
Machinery logistics construction project No 3,010.45 3,010.45 - 1,234.29 41.00% September 23, 2024 67.26 No No project (Guangdong Guoke)
Third-party medical devices
Machinery logistics construction project No 2,937.45 2,937.45 210.00 911.16 31.02% December 16, 2025 42.99 Not applicable No project (Tianjin Hengxiang)
Information system upgrade
No 15,622.60 15,622.60 1,478.20 10,357.21 66.30% December 31, 2027 Not applicable Not applicable No level construction project
Supplementary working capital No 40,000.00 40,000.00 - 40,000.00 100.00% Not applicable Not applicable Not applicable No Commitment to investment projects
61,570.50 61,570.50 1,688.20 52,502.66 -
Subtotal
Guoke Hengtai (Beijing) Medical Technology Co., Ltd.
Special report on the storage, management and use of raised funds in the first half of 2026
Investment direction of super-raised funds
Investment direction not yet determined
No 2,275.41 2,275.41 - - - Not applicable Not applicable Not applicable No funds
permanent replenishment stream
No 20,475.00 20,475.00 - 20,475.00 100.00% Not applicable Not applicable Not applicable No use of funds
Investment direction of super-raised funds
22,750.41 22,750.41 - 20,475.00 -
Subtotal
Total 84,320.91 84,320.91 1,688.20 72,977.66 - 110.25
During the actual implementation process, affected by factors such as the external macro-environment and overall changes in the industry, the overall construction progress of the "Information System Upgrade Construction Project" and "Third-Party Medical Device Logistics Construction Project" slowed down. Based on the actual progress of the current fundraising project, the company will extend the time for the project to reach the scheduled usable state:
- The date for the "information system upgrade and construction project" to reach the scheduled usable state has been extended from the originally planned May 2023 to December 2025. This matter has been reviewed and approved at the 15th meeting of the third board of directors and the sixth meeting of the third board of supervisors held on September 12, 2023.
The company held the 46th meeting of the third board of directors and the 26th meeting of the third board of supervisors on November 27, 2025. The circumstances and reasons why the company failed to achieve planned progress or expected profits
At the meeting, the "Proposal on the Extension of Part of the Investment Projects with Raised Funds" was reviewed and approved, and it was agreed that the company's "Information System Upgrading and Construction Project", an investment project with raised funds, would reach the scheduled usable state from the originally planned December 2025 to December 2027.
The part of the "Third-party Medical Device Logistics Construction Project" implemented by Tianjin Hengxiang will fully reach the expected use status in December 2025. The overall completion time of the raised investment project is less than one year, and it is not yet possible to compare whether the expected benefits have been achieved.
The part of the "Third Party Medical Device Logistics Construction Project" implemented by Guangdong Guoke did not achieve the expected benefits due to the impact of external macro-environment, overall changes in the industry and other factors during the actual implementation process.
Description of major changes in project feasibility Not applicable
For details on the amount, use and progress of the excess raised funds, please refer to the description in Section 3.6 of this report.
Guoke Hengtai (Beijing) Medical Technology Co., Ltd.
Special report on the storage, management and use of raised funds in the first half of 2026
Changes in implementation location of investment projects with raised funds Not applicable
Adjustments to the implementation methods of investment projects with raised funds Not applicable
Advance investment and replacement of raised funds in investment projects Not applicable
The use of idle raised funds to temporarily replenish working capital. For details, please refer to the description in Section 3.4 of this report. The amount and reasons for the balance of raised funds during project implementation. For details, see Section 3.5 of this report for the purpose and whereabouts of unused raised funds. For details, see Section 3.7 of this report for the problems or other situations in the use and disclosure of raised funds. For details, please refer to the explanation in Chapter 3.8 of this report. Note: 1. The above data are rounded to two decimal places. If the total does not match the sum of each sub-item, it is due to rounding during the calculation process; Note: 2. The data of "total raised funds" and "total total raised funds invested" do not include issuance fees;
Note: 3. "Total accumulated raised funds invested" only counts the investment amount and excess use amount of the raised investment projects in the situation table. The "supplementary working capital project" has a surplus of 17,800 yuan and the "third-party medical device logistics construction project" has a surplus of 17,760,600 yuan. The total permanent supplementary working capital of 17,778,400 yuan is not included in the statistics;
Note: 4. The investment in the "Third-party Medical Device Logistics Construction Project (Tianjin Hengxiang)" during the reporting period is the payment of the final payment after the project is completed.